Ubiquitin-specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Central to the recognition, signaling, and repair of DNA double-strand breaks (DSBs) are the MRE11-RAD50-NBS1 (MRN) complex and mediator of DNA damage checkpoint protein 1 (MDC1), the interplay of which is essential for initiation and amplification of the DNA damage response (DDR). The intrinsic rule governing the regulation of the function of this molecular machinery remains to be investigated. We report here that the ubiquitin-specific protease USP7 was physically associated with the MRN-MDC1 complex and that the MRN-MDC1 complex acted as a platform for USP7 to efficiently deubiquitinate and stabilize MDC1, thereby sustaining the DDR. Accordingly, depletion of USP7 impaired the engagement of the MRN-MDC1 complex and the consequent recruitment of the downstream factors p53-binding protein 1 (53BP1) and breast cancer protein 1 (BRCA1) at DNA lesions. Significantly, USP7 was overexpressed in cervical cancer, and the level of its expression positively correlated with that of MDC1 and worse survival rates for patients with cervical cancer. We demonstrate that USP7-mediated MDC1 stabilization promoted cervical cancer cell survival and conferred cellular resistance to genotoxic insults. Together, our study reveals a role for USP7 in regulating the function of the MRN-MDC1 complex and activity of the DDR, supporting the pursuit of USP7 as a potential therapeutic target for MDC1-proficient cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“DNA double-strand breaks (DSBs) are the most cytotoxic type of DNA damage, as unrepaired or inappropriate repair of DSBs will inevitably cause mutations or chromosomal aberrations and eventually lead to diseases such as cancer (2–4).”
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · cited 1×
“Deficiency or mutation of key components of the DDR pre-disposes individuals to hereditary cancer (22–25).”
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
MDC1 is a mediator of the mammalian DNA damage checkpoint
Stewart, G. S., Wang, B., Bignell, C. R., Taylor, A. M. R., & Elledge, S. J. (2003) · Nature · doi:10.1038/nature01446 · Cited by 874 · cited 2×
“org Volume 128 Number 10 October 2018 In agreement with a protective role for MDC1 in counteracting excessive, replication-associated DNA damage (14, 69, 80), we also demonstrated that, in the absence of exogenous DNA damage, USP7-promoted MDC1 stabilization is required for cervical cancer survival.”
Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804 · cited 1×
“Moreover, cotransfection of HeLa cells stably expressing FLAG-MDC1 with different amounts of USP7/WT or USP7/C223S together with HA-Ub or a ubiquitin mutant (Ub/mt) with all lysine residues replaced by arginine (50), followed by IP of cellular lysates with anti-FLAG and IB with anti-HA, showed that the levels of ubiqu…”
The MRE11 complex: starting from the ends
Stracker, T. H., & Petrini, J. H. J. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3047 · Cited by 734
53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark
Fradet-Turcotte, A., Canny, M. D., Escribano-Díaz, C., Orthwein, A., Leung, C. C. Y., Huang, H., Landry, M.-C., Kitevski-LeBlanc, J., Noordermeer, S. M., Sicheri, F., et al. (2013) · Nature · doi:10.1038/nature12318 · Cited by 686 · cited 1×
“In eukaryotic cells, ubiquitination is believed to play a key role in the assembly as well as disassembly of DDR factors at break sites (17, 20, 66, 67).”
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633 · cited 1×
“In addition, DNA damage loads associated with excessive replication, which is essential for the survival of these cells and renders cells resistant to DNA damage–based therapy (1, 26, 27).”
Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.007 · Cited by 589 · cited 1×
“…light of the observations that dysregulation of the DDR is involved in promoting tumorigenesis (53) and of the implication of USP7 in the development and progression of multiple malignancies (58–60), it is reasonable to postulate that USP7-promoted MDC1 stabilization plays a role in tumorigenesis.”
Chromatin Remodeling at DNA Double-Strand Breaks
Price, B. D., & D’Andrea, A. D. (2013) · Cell · doi:10.1016/j.cell.2013.02.011 · Cited by 588
Therapeutic opportunities within the DNA damage response
Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587 · cited 1×
“In light of the observations that dysregulation of the DDR is involved in promoting tumorigenesis (53) and of the implication of USP7 in the development and progression of multiple malignancies (58–60), it is reasonable to postulate that USP7-promoted MDC1 stabilization plays a role in tumorigenesis.”
MDC1 is required for the intra-S-phase DNA damage checkpoint
Goldberg, M., Stucki, M., Falck, J., D'Amours, D., Rahman, D., Pappin, D., Bartek, J., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature01445 · Cited by 506
Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair
Berkovich, E., Monnat, R. J., & Kastan, M. B. (2007) · Nature Cell Biology · doi:10.1038/ncb1599 · Cited by 477 · cited 7×
“Furthermore, immunofluorescence staining followed by confocal microscopic analysis indicated that endogenous USP7 was accumulated and colocalized with γ H2AX and MDC1 at UVA laser microdissection–induced DNA lesions (Figure 2D and Supplemental Figure 2B).”
InfluentialMolecular basis of USP7 inhibition by selective small-molecule inhibitors.
Turnbull, A. P., Ioannidis, S., Krajewski, W. W., Pinto-Fernandez, A., Heride, C., Martin, A. C. L., Tonkin, L. M., Townsend, E. C., Buker, S. M., Lancia, D. R., et al. (2017) · Nature · doi:10.1038/nature24451 · Cited by 463 · cited 1×
“Targeting USP7 may thus provide an effective treatment for patients with cervical cancer who undergo DNA-damaging therapy, particularly in light of recent efforts to develop a specific small-molecule antagonist toward the catalytic activity of USP7 (47, 74) or attenuate ubiquitin binding (48, 75).”
BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing
Zhao, W., Steinfeld, J. B., Liang, F., Chen, X., Maranon, D. G., Jian Ma, C., Kwon, Y., Rao, T., Wang, W., Sheng, C., et al. (2017) · Nature · doi:10.1038/nature24060 · Cited by 393
USP7 small-molecule inhibitors interfere with ubiquitin binding.
Kategaya, L., Di Lello, P., Rougé, L., Pastor, R., Clark, K. R., Drummond, J., Kleinheinz, T., Lin, E., Upton, J.-P., Prakash, S., et al. (2017) · Nature · doi:10.1038/nature24006 · Cited by 333 · cited 2×
“Targeting USP7 may thus provide an effective treatment for patients with cervical cancer who undergo DNA-damaging therapy, particularly in light of recent efforts to develop a specific small-molecule antagonist toward the catalytic activity of USP7 (47, 74) or attenuate ubiquitin binding (48, 75).”
Williams, R. S., Dodson, G. E., Limbo, O., Yamada, Y., Williams, J. S., Guenther, G., Classen, S., Glover, J. N. M., Iwasaki, H., Russell, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.07.033 · Cited by 322
Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme.
Reverdy, C., Conrath, S., Lopez, R., Planquette, C., Atmanene, C., Collura, V., Harpon, J., Battaglia, V., Vivat, V., Sippl, W., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.02.007 · Cited by 270 · cited 2×
“Targeting USP7 may thus provide an effective treatment for patients with cervical cancer who undergo DNA-damaging therapy, particularly in light of recent efforts to develop a specific small-molecule antagonist toward the catalytic activity of USP7 (47, 74) or attenuate ubiquitin binding (48, 75).”
Aymard, F., Aguirrebengoa, M., Guillou, E., Javierre, B. M., Bugler, B., Arnould, C., Rocher, V., Iacovoni, J. S., Biernacka, A., Skrzypczak, M., et al. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3387 · Cited by 263
Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.
Wang, Q., Ma, S., Song, N., Li, X., Liu, L., Yang, S., Ding, X., Shan, L., Zhou, X., Su, D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85747 · Cited by 206 · cited 1×
“Consistent with the role of USP7 reported here, we and others have revealed that USP7 is involved in the DDR and repair through regulation of distinct protein substrates (40, 60, 73).”
Self-citationMDC1 collaborates with TopBP1 in DNA replication checkpoint control
Wang, J., Gong, Z., & Chen, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201010026 · Cited by 118 · cited 1×
“org In agreement with a protective role for MDC1 in counteracting excessive, replication-associated DNA damage (14, 69, 80), we also demonstrated that, in the absence of exogenous DNA damage, USP7-promoted MDC1 stabilization is required for cervical cancer survival.”
TSPYL5 suppresses p53 levels and function by physical interaction with USP7.
Epping, M. T., Meijer, L. A. T., Krijgsman, O., Bos, J. L., Pandolfi, P. P., & Bernards, R. (2011) · Nature Cell Biology · doi:10.1038/ncb2142 · Cited by 117
USP7 counteracts SCFβTrCP- but not APCCdh1-mediated proteolysis of Claspin
Faustrup, H., Bekker-Jensen, S., Bartek, J., Lukas, J., & Mailand, N. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200807137 · Cited by 113 · cited 1×
“Interestingly, USP7 has been reported to target a panel of DDR proteins, including RNF168 (40), RNF169 (41), CHK1 (42, 43), and claspin (44).”
USP7 controls Chk1 protein stability by direct deubiquitination.
Alonso-de Vega, I., Martín, Y., & Smits, V. A. (2014) · Cell Cycle · doi:10.4161/15384101.2014.973324 · Cited by 92 · cited 1×
“Interestingly, USP7 has been reported to target a panel of DDR proteins, including RNF168 (40), RNF169 (41), CHK1 (42, 43), and claspin (44).”
USP7 deubiquitinase promotes ubiquitin-dependent DNA damage signaling by stabilizing RNF168.
Zhu, Q., Sharma, N., He, J., Wani, G., & Wani, A. A. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1007785 · Cited by 87 · cited 3×
“Given that RNF168 is also reported to be a substrate of USP7 and stabilized by USP7 (40), it seems impossible that MDC1 would be able to restore the USP7 depletion–associated effect in conditions of low abundance of RNF168.”
Agathanggelou, A., Smith, E., Davies, N. J., Kwok, M., Zlatanou, A., Oldreive, C. E., Mao, J., Da Costa, D., Yadollahi, S., Perry, T., et al. (2017) · Blood · doi:10.1182/blood-2016-12-758219 · Cited by 75 · cited 1×
“In support of this, a recent study indicated that USP7 inhibition sensitizes p53defective, chemotherapy-resistant chronic lymphocytic leukemia (CLL) cells to clinically achievable doses of chemotherapeutic agents in a murine xenograft model (76).”
Modulating the DNA damage response to improve treatment response in cervical cancer
Cossar, L. H., Schache, A. G., Risk, J. M., Sacco, J. J., Jones, N. J., & Lord, R. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.03.002 · Cited by 12 · cited 3×
“It is known that 99% of cervical cancers are associated with HPV infection, the incorporation of which results in a defective G1/S checkpoint (28, 61).”
Cited by
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Dai, X., Lu, L., Deng, S., Meng, J., Wan, C., Huang, J., Sun, Y., Hu, Y., Wu, B., Wu, G., et al. (2020) · Theranostics · doi:10.7150/thno.47137 · Cited by 288
USP7 Is a Master Regulator of Genome Stability
Valles, G. J., Bezsonova, I., Woodgate, R., & Ashton, N. W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00717 · Cited by 114
“MDC1 promotes DSB signaling by binding to histone H2AX following its phosphorylation by the repair kinase, ataxia-telangiectasia mutated (ATM) (Stewart et al., 2003).”
BackgroundInfluentialContribution of proteases to the hallmarks of aging and to age-related neurodegeneration
Rai, M., Curley, M., Coleman, Z., & Demontis, F. (2022) · Aging Cell · doi:10.1111/acel.13603 · Cited by 72
Yang, Y., Yang, C., Li, T., Yu, S., Gan, T., Hu, J., Cui, J., & Zheng, X. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2149 · Cited by 57
Self-citation
Metadata
- Authors
- Su, D., Ma, S., Shan, L., Wang, Y., Wang, Y., Cao, C., Liu, B., Yang, C., Wang, L., Tian, S., Ding, X., Liu, X., Yu, N., Song, N., Liu, L., Yang, S., Zhang, Q., Yang, F., Zhang, K., & Shi, L.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-09-04
- Volume
- 128
- Issue
- 10
- Pages
- 4280-4296
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2890820474
- Cited by
- 114
- References
- 27
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.